Canada markets closed

Axsome Therapeutics Inc (19X.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
70.20+1.20 (+1.74%)
At close: 09:59PM CEST
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2023-12-31
2022-12-31
2021-12-31
2020-12-31
Total Revenue
251,023
270,600
50,037
0
0
Cost of Revenue
24,806
26,065
5,198
0
0
Gross Profit
226,217
244,535
44,839
0
0
Operating Expenses
Research Development
116,981
97,944
57,947
58,061
70,245
Selling General and Administrative
347,902
323,123
159,254
66,646
28,897
Total Operating Expenses
471,275
427,442
221,340
124,707
99,088
Operating Income or Loss
-245,058
-182,907
-176,501
-124,707
-99,088
Interest Expense
5,271
6,453
7,335
5,696
2,566
Total Other Income/Expenses Net
-47,668
-48,918
-3,298
-
-1,247
Income Before Tax
-297,997
-238,278
-187,134
-130,403
-102,901
Income Tax Expense
-1,620
960
0
0
-
Income from Continuing Operations
-296,377
-239,238
-187,134
-130,403
-102,901
Net Income
-296,377
-239,238
-187,134
-130,403
-102,901
Net Income available to common shareholders
-296,377
-239,238
-187,134
-130,403
-102,901
Basic EPS
-4.57
-5.27
-4.60
-3.47
-2.77
Diluted EPS
-4.57
-5.27
-4.60
-3.47
-2.77
Basic Average Shares
44,457
45,425
40,656
37,619
37,207
Diluted Average Shares
44,457
45,425
40,656
37,619
37,207